Tesamorelin helps lower blood fat levels in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available

Scientific Claim

Tesamorelin use is associated with improvements in triglyceride levels in HIV-1-infected patients with lipodystrophy.

Original Statement

“improvement in triglycerides”

From study:Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

Evidence Quality Assessment

Claim Status

overstated

Study Design Support

Design cannot support claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The abstract uses 'improvement' which implies causation, but study design is unknown, so 'associated with' is appropriate.

Evidence from Studies

Supporting (1)

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

Case-Control Study

Human

2011 Jan

Contradicting (0)

No contradicting evidence found

Source Study

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

Score: 20

DOI: 10.1586/eem.10.83

Similar Assertions

Tesamorelin doesn't significantly change the fat under the skin in people with HIV-related body shape changes. This finding is from the abstract summary - full study details were not available

92%

Taking tesamorelin is linked to less belly fat in people with HIV who have body shape changes. This finding is from the abstract summary - full study details were not available

89%

Stopping tesamorelin causes the positive effects to go away in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available

87%

Taking tesamorelin makes people with HIV feel better about their belly appearance. This finding is from the abstract summary - full study details were not available

85%

Tesamorelin helps lower triglycerides, a type of fat in the blood, by about 12% in HIV patients on medication compared to those not taking it. This finding is from the abstract summary - full study details were not available

83%